

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Jul 2026

Evaluation of therapeutic effects of topical atorvastatin in postoperative ulcers: A randomized triple-blind placebo-controlled trial

Protocol summary

Study aim

Comparison of the effect of simple topical and nano-local atorvastatin formulations on surgical laparotomy wound healing

Design

This triple-blind clinical trial randomized in phase 3 was performed with parallel groups of 60 patients (20 per group). The first group receiving atorvastatin nano-emulgel, the second group receiving simple atorvastatin emulgel, and the third group receiving placebo emulgel. Number randomization was performed using Random Allocation software using the permutation block method. Patients will receive the drug twice a day for fourteen days.

Settings and conduct

Surgery unit of Dr. Rahnemoon Hospital of Yazd

Participants/Inclusion and exclusion criteria

Inclusion criteria: 1) Candidates for laparotomy surgery 2) Sufficient literacy to fill out a consent form, understand the study, use the drug, and report pain and possible side effects Exclusion criteria: 1) Pregnant and lactating women 2) Patients with any peripheral or central neuropathic pain 3) Patients with a history of alcohol abuse or opioid dependence 4) Patients with a history of psychosis 5) Patients with a history of inflammatory disease who cannot discontinue NSAIDs or analgesics. 6) Patients with oral atorvastatin

Intervention groups

Group 1: Patients treated with atorvastatin nano emulgel 1% The second group: patients treated with atorvastatin emulgel 1% Group 3: Patients treated with placebo

Main outcome variables

Redness Edema Ecchymosis Wound size Wound Secretion

General information

Reason for update

The need for some changes during the trial

Acronym

IRCT registration information

IRCT registration number: **IRCT20190810044500N3**

Registration date: **2020-04-10, 1399/01/22**

Registration timing: **registered_while_recruiting**

Last update: **2023-03-14, 1401/12/23**

Update count: **1**

Registration date

2020-04-10, 1399/01/22

Registrant information

Name

Fatemeh Saghafi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 35 3820 3419

Email address

f.saghafi@ssu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-11-13, 1398/08/22

Expected recruitment end date

2020-07-22, 1399/05/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of therapeutic effects of topical atorvastatin in postoperative ulcers: A randomized triple-blind placebo-controlled trial

Public title

Effect of atorvastatin on ulcer

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Candidates for laparotomy surgery over 18 years old
Sufficient literacy to fill out a consent form, understand the study, use the drug, report pain and possible side effects

Exclusion criteria:

Pregnant and lactating women Patients with any peripheral or central neuropathic pain Patients with a history of psychosis Patients with a history of inflammatory disease who cannot discontinue NSAIDs or analgesics. Patients with oral atorvastatin

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Number randomization was performed using Random Allocation software using permutation block method. The numbers are sorted into three blocks and assigned to the codes A, B and C. That the codes A, B, and C are unknown for the researcher.

Blinding (investigator's opinion)

Triple blinded

Blinding description

Blindness was performed on clinical caregivers, including physicians and nurses, as well as variables assessors and data analysts. In this case, the three drugs nano-emulsifiers of atorvastatin and simple emulsifiers of atorvastatin and placebo with the letters A, B and C are randomly named by another person and this person is not responsible in this study.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Faculty of Ethics of Medical Sciences - Shahid Sadoughi University of Medical Sciences

Street address

Shahid Sadoughi University of Medical Sciences, Shohaday gomnam Blvd, Yazd

City

Yazd

Province

Yazd

Postal code

8915173143

Approval date

2019-11-03, 1398/08/12

Ethics committee reference number

IR.SSU.MEDICINE.REC.1398.196

Health conditions studied**1****Description of health condition studied**

Post-operative wounds

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

Redness

Timepoint

Before the start of the intervention - The first day -The seventh day -The fourteenth day

Method of measurement

Redness, Oedema, Ecchymosis, Discharge, Approximation (REEDA) scale

2**Description**

Oedema

Timepoint

Before the start of the intervention - The first day -The seventh day -The fourteenth day

Method of measurement

REEDA Scale

3**Description**

Ecchymosis

Timepoint

Before the start of the intervention - The first day -The seventh day -The fourteenth day

Method of measurement

REEDA Scale

4

Description

Wound Secretion

Timepoint

Before the start of the intervention - The first day -The seventh day -The fourteenth day

Method of measurement

REEDA Scale

5

Description

Approximation

Timepoint

Before the start of the intervention - The first day -The seventh day -The fourteenth day

Method of measurement

REEDA Scale

Secondary outcomes

1

Description

Quality of Life

Timepoint

On days 1, 7 and 14

Method of measurement

According to the Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30 (version 3)

2

Description

visual analog scale (VAS)

Timepoint

baseline, days 1, 2, , and 14

Method of measurement

The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')

3

Description

unexpected adverse effects

Timepoint

At the end of the study

Method of measurement

Examining and asking the patient

Intervention groups

1

Description

Intervention group: Atorvastatin Emulgel

Category

Treatment - Drugs

2

Description

Control group: Placebo Emulgel

Category

Placebo

3

Description

Intervention group: Atorvastatin Nano-Emulgel

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Rahnemon Hospital

Full name of responsible person

Javad Zarekamali

Street address

Alley 20,Pasdaran Blvd,Yazd

City

Yazd

Province

Yazd

Postal code

8949153678

Phone

+98 35 3823 7634

Email

javad1995.zare@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Yazd University of Medical Sciences

Full name of responsible person

Masoud Mirzaei

Street address

Bahonar Square

City

Yazd

Province

Yazd

Postal code

9856783459

Phone

+98 35 3146 2056

Email

mmirzaei@ssu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source
Shahid Sadoughi University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Fatemeh Saghafe
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Professor Hesabi Blvd., Yazd Province, Yazd, Iran
City
Yazd
Province
Yazd
Postal code
۸۹۱۵۱۷۳۱۴۹
Phone
+98 35 3820 3419
Email
F.saghafi@ssu.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Fateme Saghafe
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Yazd-Yazd-Shohaday gomnam Blvd-Shahid Sadoughi
University of Medical Sciences
City

Yazd
Province
Yazd
Postal code
8915173143
Phone
+98 35 3820 3419
Email
Saghfi.Fa@gmail.comhs

Person responsible for updating data

Contact

Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Fatemeh Saghafe
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Professor Hesabi Blvd., Yazd Province, Yazd, Iran
City
Yazd
Province
Yazd
Postal code
۸۹۱۵۱۷۳۱۴۹
Phone
+98 35 3820 3419
Email
F.saghafi@ssu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available